{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:33:59Z","timestamp":1790721239253,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anthracycline-induced cardiotoxicity remains a major limitation of cancer therapy, and effective preventive strategies are lacking. Topoisomerase IIb has been implicated as a central driver of this toxicity, suggesting that epigenetic regulators may interfere with the\u00a0pathological cardiac response. Here, we show that doxorubicin promotes topoisomerase IIb accumulation at cardiomyocyte-specific gene promoters (e.g.,\n                    <jats:italic>Actc1, Myl2<\/jats:italic>\n                    , and\n                    <jats:italic>Myh7)<\/jats:italic>\n                    overlapping myocyte enhancer factor 2 binding sites and enhances myocyte enhancer factor 2 -dependent transcription. This response is attenuated by the pan-histone deacetylase inhibitor suberoylanilide hydroxamic acid. Suberoylanilide hydroxamic acid -mediated cardioprotection requires class IIa histone deacetylases, as genetic loss of HDAC4 abolishes its effect. Mechanistically, suberoylanilide hydroxamic acid induces acetylation of the chaperone 14-3-3, disrupting its interaction with HDAC4\/5, promoting their nuclear accumulation, and repressing myocyte enhancer factor 2 - driven transcription. In vivo, suberoylanilide hydroxamic acid mitigates doxorubicin-induced cardiotoxicity. These findings identify histone deacetylase inhibition as a cardioprotective repurposing strategy and reveal a mechanistic link between epigenetic regulation and anthracycline-associated cardiotoxicity.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-77428-w","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:23:24Z","timestamp":1788528204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3168-0588","authenticated-orcid":false,"given":"Benay","family":"Eksi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synje","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannek","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3085-1282","authenticated-orcid":false,"given":"Markus B.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Valadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard M.","family":"Schanze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vighnesh","family":"Sunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Steimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-1698","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timon","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo A.","family":"Katus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-378X","authenticated-orcid":false,"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-2699","authenticated-orcid":false,"given":"Johannes","family":"Backs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5077-8580","authenticated-orcid":false,"given":"Lorenz H.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"77428_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm, K. N. & Tyler, D. J. The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovasc. Drugs Ther. 34, 255\u2013269 https:\/\/doi.org\/10.1007\/s10557-020-06941-x (2020).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"77428_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","volume":"523","author":"X Yu","year":"2020","unstructured":"Yu, X. et al. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem. Biophys. Res. Commun. 523, 140\u2013146 https:\/\/doi.org\/10.1016\/j.bbrc.2019.12.027 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"77428_CR3","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-08-2788","volume":"15","author":"RL Piekarz","year":"2009","unstructured":"Piekarz, R. L. & Bates, S. E. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res. 15, 3918\u20133926 https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2788 (2009).","journal-title":"Clin. Cancer Res."},{"key":"77428_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","volume":"118","author":"CG Lenneman","year":"2016","unstructured":"Lenneman, C. G. & Sawyer, D. B. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ. Res. 118, 1008\u20131020 https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.303633 (2016).","journal-title":"Circ. Res."},{"key":"77428_CR5","doi-asserted-by":"publisher","first-page":"28930","DOI":"10.1074\/jbc.M303113200","volume":"278","author":"CL Antos","year":"2003","unstructured":"Antos, C. L. et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278, 28930\u201328937 https:\/\/doi.org\/10.1074\/jbc.M303113200 (2003).","journal-title":"J. Biol. Chem."},{"key":"77428_CR6","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1073\/pnas.1015081108","volume":"108","author":"DJ Cao","year":"2011","unstructured":"Cao, D. J. et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. USA 108, 4123\u20134128 https:\/\/doi.org\/10.1073\/pnas.1015081108 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77428_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3109\/10428194.2015.1075019","volume":"57","author":"B Holkova","year":"2016","unstructured":"Holkova, B. et al. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk. Lymphoma 57, 635\u2013643 https:\/\/doi.org\/10.3109\/10428194.2015.1075019 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"77428_CR8","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","volume":"15","author":"A Badros","year":"2009","unstructured":"Badros, A. et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res 15, 5250\u20135257 https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2850 (2009).","journal-title":"Clin. Cancer Res"},{"key":"77428_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2016.05.018","volume":"64","author":"T Schmitt","year":"2016","unstructured":"Schmitt, T. et al. Vorinostat in refractory soft tissue sarcomas\u2014results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). Eur. J. Cancer 64, 74\u201382 https:\/\/doi.org\/10.1016\/j.ejca.2016.05.018 (2016).","journal-title":"Eur. J. Cancer"},{"key":"77428_CR10","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00018-013-1516-9","volume":"71","author":"LH Lehmann","year":"2014","unstructured":"Lehmann, L. H., Worst, B. C., Stanmore, D. A. & Backs, J. Histone deacetylase signaling in cardioprotection. Cell. Mol. Life Sci. 71, 1673\u20131690 https:\/\/doi.org\/10.1007\/s00018-013-1516-9 (2014).","journal-title":"Cell. Mol. Life Sci."},{"key":"77428_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1172\/JCI19137","volume":"112","author":"H Kook","year":"2003","unstructured":"Kook, H. et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Investig. 112, 863\u2013871 https:\/\/doi.org\/10.1172\/JCI19137 (2003).","journal-title":"J. Clin. Investig."},{"key":"77428_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nm1552","volume":"13","author":"CM Trivedi","year":"2007","unstructured":"Trivedi, C. M. et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med. 13, 324\u2013331 https:\/\/doi.org\/10.1038\/nm1552 (2007).","journal-title":"Nat. Med."},{"key":"77428_CR13","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.1128\/MCB.21.17.5992-6005.2001","volume":"21","author":"AH Wang","year":"2001","unstructured":"Wang, A. H. & Yang, X. J. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol. Cell. Biol. 21, 5992\u20136005 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"77428_CR14","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1128\/MCB.01611-07","volume":"28","author":"J Backs","year":"2008","unstructured":"Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T. A. & Olson, E. N. Histone deacetylase 5 acquires calcium\/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol. Cell. Biol. 28, 3437\u20133445 https:\/\/doi.org\/10.1128\/MCB.01611-07 (2008).","journal-title":"Mol. Cell. Biol."},{"key":"77428_CR15","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1128\/MCB.24.19.8467-8476.2004","volume":"24","author":"S Chang","year":"2004","unstructured":"Chang, S. et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24, 8467\u20138476 https:\/\/doi.org\/10.1128\/MCB.24.19.8467-8476.2004 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"77428_CR16","doi-asserted-by":"publisher","first-page":"H252","DOI":"10.1152\/ajpheart.00149.2014","volume":"307","author":"KM Demos-Davies","year":"2014","unstructured":"Demos-Davies, K. M. et al. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am. J. Physiol. Heart Circ. Physiol. 307, H252\u2013H258 https:\/\/doi.org\/10.1152\/ajpheart.00149.2014 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"77428_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1097-2765(01)00429-4","volume":"9","author":"W Fischle","year":"2002","unstructured":"Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT\/N-CoR. Mol. Cell 9, 45\u201357 (2002).","journal-title":"Mol. Cell"},{"key":"77428_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/43710","volume":"401","author":"MS Finnin","year":"1999","unstructured":"Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188\u2013193 https:\/\/doi.org\/10.1038\/43710 (1999).","journal-title":"Nature"},{"key":"77428_CR19","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1128\/MCB.20.18.6904-6912.2000","volume":"20","author":"AH Wang","year":"2000","unstructured":"Wang, A. H. et al. Regulation of histone deacetylase 4 by binding of 14-3-3 proteins. Mol. Cell. Biol. 20, 6904\u20136912 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"77428_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1083\/jcb.201105063","volume":"195","author":"J Backs","year":"2011","unstructured":"Backs, J. et al. Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J. Cell Biol. 195, 403\u2013415 (2011).","journal-title":"J. Cell Biol."},{"key":"77428_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep25333","volume":"6","author":"A Maillet","year":"2016","unstructured":"Maillet, A. et al. Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Sci. Rep. 6, 25333 https:\/\/doi.org\/10.1038\/srep25333 (2016).","journal-title":"Sci. Rep."},{"key":"77428_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1175371","volume":"325","author":"C Choudhary","year":"2009","unstructured":"Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834\u2013840 https:\/\/doi.org\/10.1126\/science.1175371 (2009).","journal-title":"Science"},{"key":"77428_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm.4452","volume":"24","author":"LH Lehmann","year":"2018","unstructured":"Lehmann, L. H. et al. A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway. Nat. Med. 24, 62\u201372 https:\/\/doi.org\/10.1038\/nm.4452 (2018).","journal-title":"Nat. Med."},{"key":"77428_CR24","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","volume":"109","author":"ET Yeh","year":"2004","unstructured":"Yeh, E. T. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109, 3122\u20133131 https:\/\/doi.org\/10.1161\/01.CIR.0000133187.74800.B9 (2004).","journal-title":"Circulation"},{"key":"77428_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.105.559724","volume":"113","author":"HJ Kee","year":"2006","unstructured":"Kee, H. J. et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113, 51\u201359 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.559724 (2006).","journal-title":"Circulation"},{"key":"77428_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrd2193","volume":"6","author":"TA McKinsey","year":"2007","unstructured":"McKinsey, T. A. & Kass, D. A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 6, 617\u2013635 https:\/\/doi.org\/10.1038\/nrd2193 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"77428_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.tig.2004.02.002","volume":"20","author":"TA McKinsey","year":"2004","unstructured":"McKinsey, T. A. & Olson, E. N. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 20, 206\u2013213 https:\/\/doi.org\/10.1016\/j.tig.2004.02.002 (2004).","journal-title":"Trends Genet."},{"key":"77428_CR28","doi-asserted-by":"publisher","unstructured":"Burhenne, J. et al. Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. Cancer Chemother. Pharmacol. https:\/\/doi.org\/10.1007\/s00280-017-3357-y (2017).","DOI":"10.1007\/s00280-017-3357-y"},{"key":"77428_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/cam4.2728","volume":"9","author":"VM Villalobos","year":"2020","unstructured":"Villalobos, V. M. et al. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. Cancer Med. 9, 882\u2013893 https:\/\/doi.org\/10.1002\/cam4.2728 (2020).","journal-title":"Cancer Med."},{"key":"77428_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.107.098046","volume":"51","author":"D Frank","year":"2008","unstructured":"Frank, D. et al. Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension 51, 309\u2013318 https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.098046 (2008).","journal-title":"Hypertension"},{"key":"77428_CR31","doi-asserted-by":"publisher","first-page":"106926","DOI":"10.1016\/j.phrs.2023.106926","volume":"196","author":"Y Pang","year":"2023","unstructured":"Pang, Y. et al. The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo. Pharm. Res. 196, 106926 https:\/\/doi.org\/10.1016\/j.phrs.2023.106926 (2023).","journal-title":"Pharm. Res."},{"key":"77428_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.149","volume":"46","author":"SJ Lee","year":"2014","unstructured":"Lee, S. J. et al. Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells. Exp. Mol. Med. 46, e76 https:\/\/doi.org\/10.1038\/emm.2013.149 (2014).","journal-title":"Exp. Mol. Med."},{"key":"77428_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jcmgh.2021.11.012","volume":"13","author":"S Gallage","year":"2022","unstructured":"Gallage, S. et al. Spontaneous cholemia in C57BL\/6 mice predisposes to liver cancer in NASH. Cell Mol. Gastroenterol. Hepatol. 13, 875\u2013878 https:\/\/doi.org\/10.1016\/j.jcmgh.2021.11.012 (2022).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"77428_CR34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI27438","volume":"116","author":"J Backs","year":"2006","unstructured":"Backs, J., Song, K., Bezprozvannaya, S., Chang, S. & Olson, E. N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Investig. 116, 1853\u20131864 https:\/\/doi.org\/10.1172\/JCI27438 (2006).","journal-title":"J. Clin. Investig."},{"key":"77428_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/CIRCULATIONAHA.118.034624","volume":"139","author":"T Seeger","year":"2019","unstructured":"Seeger, T. et al. A premature termination codon mutation in MYBPC3 causes hypertrophic cardiomyopathy via chronic activation of nonsense-mediated decay. Circulation 139, 799\u2013811 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034624 (2019).","journal-title":"Circulation"},{"key":"77428_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yjmcc.2021.09.001","volume":"162","author":"D Finke","year":"2022","unstructured":"Finke, D. et al. Histone deacetylase 4 deletion broadly affects cardiac epigenetic repression and regulates transcriptional susceptibility via H3K9 methylation. J. Mol. Cell. Cardiol. 162, 119\u2013129 https:\/\/doi.org\/10.1016\/j.yjmcc.2021.09.001 (2022).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"77428_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1161\/CIRCRESAHA.115.306993","volume":"117","author":"S Doroudgar","year":"2015","unstructured":"Doroudgar, S. et al. Hrd1 and ER-associated protein degradation, ERAD, are critical elements of the adaptive ER stress response in cardiac myocytes. Circ. Res. 117, 536\u2013546 https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306993 (2015).","journal-title":"Circ. Res."},{"key":"77428_CR38","doi-asserted-by":"publisher","first-page":"E1848","DOI":"10.1073\/pnas.1200250109","volume":"109","author":"X Lian","year":"2012","unstructured":"Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. USA 109, E1848\u2013E1857 https:\/\/doi.org\/10.1073\/pnas.1200250109 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77428-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:23:26Z","timestamp":1788528206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77428-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77428"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77428-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.H.L. has served on the advisory board for Janssen-Cilag GmbH, Daiichi Sankyo, AstraZeneca, and Teysuno as an external expert for AstraZeneca and received speakers\u2019 honoraria from Novartis, Lilly, and MSD. N.F. and J.Ba. are co-founders of REVIER Therapeutics, which develops class IIa HDAC inhibitors to treat HFpEF. N.F. has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, and Novartis.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9505"}}